Enanta Pharmaceuticals (NASDAQ:ENTA) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a sell rating in a report published on Saturday morning.

Several other research firms have also issued reports on ENTA. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, June 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Price Performance

Shares of ENTA opened at $13.47 on Friday. Enanta Pharmaceuticals has a 1 year low of $7.05 and a 1 year high of $17.15. The company has a market capitalization of $392.31 million, a price-to-earnings ratio of -5.59 and a beta of 0.98. The business has a 50-day moving average of $13.43 and a 200-day moving average of $13.46.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The company had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -2.36 EPS for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ENTA. Wellington Management Group LLP increased its holdings in Enanta Pharmaceuticals by 8.9% in the second quarter. Wellington Management Group LLP now owns 81,633 shares of the biotechnology company’s stock worth $1,190,000 after purchasing an additional 6,673 shares in the last quarter. Bank of America Corp DE acquired a new position in Enanta Pharmaceuticals in the second quarter valued at approximately $314,000. Jupiter Topco LLC acquired a new position in Enanta Pharmaceuticals in the second quarter valued at approximately $53,252,000. ADAR1 Capital Management LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $19,603,000. Finally, Legal & General Group Plc bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter worth approximately $41,000. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.